Bristol Myers Squibb BMY Insider Ownership

NYSE BMY

$58.84 -0.91 (-1.52%)

At close: Oct 19, 2026 · 4:00 PM EDT

Insider Holdings by Owner

1.46Mn Shares

Insider Ownership Statistics

as of 30 Sep, 2026

Insider Ownership

0.054%

▲+0.0009% pp QoQ

Shares Held by Insiders

1.11Mn

filed for Sep 2026

▲+1.78% QoQ

Shares Outstanding

2.04Bn

2,042,714,656 shares

Direct Holdings

889.49K

Indirect: 218.88K

Net Shares Traded (QoQ)

+19.37K

net buying in Sep 2026

Insiders Holding Shares

with Form 4 holdings on file

Shares Owned by Insiders

Shares held % of outstanding

Latest —

Average ownership —

Peak ownership —

Shares Purchased/Sold by Insiders

Bought Sold

Latest quarter —

Net over range —

Buying quarters —

Insider Ownership Summary

Updated Oct 11, 2026

Over the past 12 months, Bristol Myers Squibb insiders sold $2.29 million of stock on the open market (36.75K shares) and made no open-market purchases.

Behind Bristol Myers Squibb's open-market sales in the past 12 months were 3 insiders, and no insider bought.
The largest open-market sales of BMY in the past 12 months were by David V. Elkins (EVP, Chief Financial Officer), totaling $1.85 million (30K shares), most recently on April 1, 2026.
The latest open-market trade in BMY stock by an insider was a sale of 6.25K shares for $403,498 by Cristian Massacesi (EVP, Chief Med Offr, Head of Development) on September 9, 2026.
Outside the open market, Bristol Myers Squibb insiders acquired 353.66K shares through option exercises and conversions and gave up 120.7K shares to cover taxes or exercise prices over the past 12 months.
Per Business Quant data, Bristol Myers Squibb insiders hold 1.11Mn shares in total based on their latest Form 4 filings, up 1.98% from 1.09Mn shares at the end of Q2 2026.
By type of ownership, BMY insiders hold 80.29% of their shares directly (891.72K shares) and 19.71% indirectly (218.88K shares).
Per Business Quant, 17 insiders of BMY hold shares, counting officers, directors and 10% owners who have filed a Form 4 in the past two years.
Bristol Myers Squibb's three biggest insider holders are Sandra Leung (EVP, General Counsel, 457.73K shares), David V. Elkins (EVP, Chief Financial Officer, 159.25K shares) and Christopher S. Boerner (Chief Executive Officer, 146.89K shares), based on their latest Form 4 filings.
The holding of Sandra Leung makes up 41.22% of all shares held by Bristol Myers Squibb insiders.
Institutions accounted for 81.81% of BMY's outstanding shares in Q2 2026, insiders about 0.05% per their latest Form 4 filings, and other investors, including the public, about 18.14%.
A total of 62 Form 4 filings with transactions in Bristol Myers Squibb stock were made over the past 12 months, by 24 insiders.
This summary of Bristol Myers Squibb insider activity covers Form 4 filings through October 5, 2026.

Form 4 Holdings

Insiders Holding BMY

Insiders 24

Shares held 1.46Mn

Of outstanding 0.071%

#	Insider	Position	Direct	Total	Share of Insiders	Last Filed
1	Giovanni Caforio	Executive Chair Of The Board	432,266	432,266	29.7%	12 Mar, 2024
2	Sandra Leung	Evp, General Counsel	364,296	364,296	25.0%	12 Mar, 2025
3	David V Elkins	Evp, Chief Financial Officer	159,248	159,248	10.9%	02 Apr, 2026
4	Samit Hirawat	Evp,Chief Med.Offr.,Drug Dev.	83,513	83,513	5.7%	29 Apr, 2025
5	Rupert Vessey	Evp President, Research	47,751	47,751	3.3%	04 May, 2023
6	Theodore R. Ii Samuels	Director	35,500	35,500	2.4%	21 Nov, 2023
7	Elizabeth Mily	Evp, Strategy Bd	34,734	34,734	2.4%	04 Apr, 2023
8	Julia A Haller	Director	34,079	34,079	2.3%	16 Jun, 2026
9	Gregory Scott Meyers	Evp, Chief Digital Tech Off.	30,361	30,361	2.1%	12 Mar, 2026
10	Ann Powell	Evp, Chief Human Resources	27,868	27,868	1.9%	28 Aug, 2023
11	Karin Shanahan	Evp, Chief Supply Chain Ops	25,888	25,888	1.8%	02 Apr, 2026
12	Robert M Plenge	Evp, Chief Research Officer	21,528	21,528	1.5%	12 Mar, 2026
13	Christopher S. Boerner	Chief Executive Officer	21,451	21,451	1.5%	12 Mar, 2026
14	Adam Lenkowsky	Evp, Chief Commercial Officer	19,706	19,706	1.4%	05 May, 2026
15	Cristian Massacesi	Evp,Chief Med Offr,Head Of Dev	18,748	18,748	1.3%	10 Sep, 2026
16	Phil M Holzer	Svp And Controller	16,862	16,862	1.2%	26 Aug, 2026
17	Karen Murphy Santiago	Svp Controller	16,704	16,704	1.1%	16 Mar, 2022
18	Benjamin Hickey	President, Rayzebio Org.	16,672	16,672	1.1%	03 Mar, 2026
19	Cari Gallman	Evp, General Counsel	15,876	15,876	1.1%	05 Oct, 2026
20	Bartie Wendy Short	Evp, Corporate Affairs	12,684	12,684	0.9%	03 Sep, 2026
21	Lynelle Hoch	President, Cell Therapy Org.	8,210	8,210	0.6%	12 Mar, 2026
22	Ahn Amanda Poole	Evp, Chief People Officer	7,094	7,094	0.5%	12 Mar, 2026
23	Michelle Weese	Evp, Corporate Affairs	3,453	3,453	0.2%	05 Jul, 2023
24	Sharon Greenlees	Svp Controller	609	609	0.0%	03 May, 2023

Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.

Form 4 Filings

6,511 Insider Transactions

Source SEC Form 4

Latest quarter Sep 2026

Date	Insider	Position	Transaction	Shares	Price	Value	Shares Held After	Ownership
02 Oct, 2026	Cari Gallman	Evp, General Counsel	Acquired M	4,559	$0.00	$0	18,208	Direct
02 Oct, 2026	Cari Gallman	Evp, General Counsel	Disposed F	2,332	$61.15	$142.60K	15,876	Direct
02 Oct, 2026	Cari Gallman	Evp, General Counsel	Disposed M	4,559	$0.00	$0	0	Direct
30 Sep, 2026	Phyllis R Yale	Director	Acquired A	561	$62.40	$35.00K	45,980	Direct
30 Sep, 2026	Peter J Arduini	Director	Acquired A	561	$62.40	$35.00K	74,077	Direct
30 Sep, 2026	Derica W Rice	Director	Acquired A	621	$62.40	$38.75K	42,085	Direct
30 Sep, 2026	Michael R. Mcmullen	Director	Acquired A	561	$62.40	$35.00K	17,051	Direct
30 Sep, 2026	Theodore R. Ii Samuels	Director	Acquired A	821	$62.40	$51.25K	71,859	Direct
09 Sep, 2026	Cristian Massacesi	Evp,Chief Med Offr,Head Of Dev	Disposed S	6,249	$64.57	$403.50K	18,748	Direct
01 Sep, 2026	Bartie Wendy Short	Evp, Corporate Affairs	Acquired M	1,236	$66.92	$82.71K	13,317	Direct
01 Sep, 2026	Bartie Wendy Short	Evp, Corporate Affairs	Disposed F	633	$66.92	$42.36K	12,684	Direct
01 Sep, 2026	Bartie Wendy Short	Evp, Corporate Affairs	Disposed M	1,236	$0.00	$0	0	Direct
25 Aug, 2026	Phil M Holzer	Svp And Controller	Disposed S	500	$67.50	$33.75K	16,862	Direct
01 Aug, 2026	Cristian Massacesi	Evp,Chief Med Offr,Head Of Dev	Acquired M	51,172	$0.00	$0	51,172	Direct
01 Aug, 2026	Cari Gallman	Evp, General Counsel	Acquired M	1,061	$0.00	$0	14,192	Direct
01 Aug, 2026	Cristian Massacesi	Evp,Chief Med Offr,Head Of Dev	Disposed F	26,175	$65.31	$1.71Mn	24,997	Direct
01 Aug, 2026	Cari Gallman	Evp, General Counsel	Disposed F	543	$65.31	$35.46K	13,649	Direct
01 Aug, 2026	Cari Gallman	Evp, General Counsel	Disposed M	1,061	$0.00	$0	0	Direct
01 Aug, 2026	Cristian Massacesi	Evp,Chief Med Offr,Head Of Dev	Disposed M	51,172	$0.00	$0	153,519	Direct
30 Jun, 2026	Michael R. Mcmullen	Director	Acquired A	607	$57.62	$35.00K	16,333	Direct

Showing 1 to 20 of 6,511 transactions